1. Academic Validation
  2. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms

Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms

  • Antimicrob Agents Chemother. 2013 May;57(5):2401-4. doi: 10.1128/AAC.02580-12.
Ellie J C Goldstein 1 Diane M Citron Kerin L Tyrrell C Vreni Merriam
Affiliations

Affiliation

  • 1 RM Alden Research Laboratory, Culver City, California, USA. ejcgmd@aol.com
Abstract

We studied the comparative in vitro activity of GSK2251052, a novel boron leucyl-tRNA synthetase inhibitor, against 916 clinical anaerobic isolates using CLSI methods. The GSK MIC50/MIC90 for all isolates tested were 2 and 4 μg/ml, and the MIC90s against 302 Bacteroides fragilis and Bacteroides thetaiotaomicron strains were 4 and 8 μg/ml, respectively. All Clostridium perfringens strains had GSK2251052 MICs of >32 μg/ml. There was no relationship between increased MICs for any Other Antibiotics and that of GSK2251052.

Figures
Products